TY  - JOUR
T1  - The increase in Aspergillus infections during and after the COVID-19 pandemic
AU  - Oğuz, Oğuzhan
AU  - Öztürk, Zeynel
AU  - Bayar Muluk, Nuray
AU  - Yazır, Mustafa
AU  - Özdemir, İmran
AU  - Cingi, Cemal
PY  - 2025
DA  - March
Y2  - 2025
DO  - 10.38053/acmj.1620027
JF  - Anatolian Current Medical Journal
JO  - Anatolian Curr Med J / ACMJ / acmj
PB  - MediHealth Academy Yayıncılık
WT  - DergiPark
SN  - 2718-0115
SP  - 261
EP  - 265
VL  - 7
IS  - 2
LA  - en
AB  - This paper aims to identify the correlation between Aspergillus infections and the COVID-19 pandemic. The literature review used PubMed, EBSCO, Proquest Central at Kırıkkale University, Google, and Google Scholar. Between 2024 and 1980, the keywords “Aspergillus," “aspergillosis,” “invasive pulmonary aspergillosis,” “IPA,” “COVID-19-associated pulmonary aspergillosis,” “CAPA,” and “COVID-19” were searched. An association between COVID-19 pneumonia and invasive pulmonary aspergillosis (IPA), a complication seen in patients with severe respiratory syndromes, has been recently demonstrated, and the clinical features of COVID-19-associated pulmonary aspergillosis (CAPA) have been detailed. Due to diagnostic delays and the quick deterioration of respiratory diseases, infections caused by the Aspergillus genus are frequently recognized after the fact, which is a sad reality. From direct angioinvasion to hypersensitivity reactions, Aspergillus may inflict various human diseases. Invasive Aspergillus infections are sporadic in immunocompetent people and nearly always affect those immunosuppressed due to lung illness, immunosuppressive medication, or immunodeficiency. Aspergillus fumigatus (A. fumigatus) was found in most COVID-19 patients, and CAPA was also detected in several of these individuals. Also, patients with severe respiratory illnesses, like influenza and MERS-CoV, have been found to have multiple instances of IPA as super-infections. The function of antifungal prophylaxis in CAPA is unknown even though A. fumigatus was detected before the start of CAPA. On the other hand, voriconazole medication may be effective if begun right after.
KW  - Aspergillus
KW  - invasive pulmonary aspergillosis
KW  - COVID-19 associated pulmonary aspergillosis
KW  - COVID-19
KW  - Aspergillus 
fumigatus
CR  - Trovato L, Calvo M, Migliorisi G, Astuto M, Oliveri F, Oliveri S. Fatal VAP-related pulmonary aspergillosis by Aspergillus niger in a positive COVID-19 patient. Respir Med Case Rep. 2021;32:101367. doi:10.1016/j.rmcr.2021.101367
CR  - Salmanton-García J, Sprute R, Stemler J, et al. COVID-19-Associated pulmonary aspergillosis, March-August 2020. Emerg Infect Dis. 2021; 27(4):1077-1086. doi:10.3201/eid2704.204895
CR  - Koehler P, Meis JF, Ostrosky-Zeichner L, et al. COVID-19/influenza-associated pulmonary aspergillosis—management. Uniklinik Köln: Köln, Germany, 2020. [cited 2020 May 30]. https://repository.publisso.de/resource/frl%3A6421494
CR  - Beer KD, Jackson BR, Chiller T, Verweij PE, Van de Veerdonk FL, Wauters J. Does pulmonary aspergillosis complicate coronavirus disease 2019? Crit Care Explor. 2020;2(9):e0211. doi:10.1097/CCE. 0000000000000211
CR  - Costantini C, van de Veerdonk FL, Romani L. Covid-19–associated pulmonary aspergillosis: the other side of the coin. Vaccines (Basel). 2020;8(4):713. doi:10.3390/vaccines8040713
CR  - Arastehfar A, Carvalho A, van de Veerdonk FL, et al. COVID-19-associated pulmonary aspergillosis (CAPA)—from immunology to treatment. J Fungi (Basel). 2020;6(2):91. doi:10.3390/jof6020091
CR  - van Arkel ALE, Rijpstra TA, Belderbos HNA, van Wijngaarden P, Verweij PE, Bentvelsen RG. COVID-19-associated pulmonary aspergillosis. Am J Respir Crit Care Med. 2020;202(1):132-135. doi:10.1164/rccm.202004-1038LE
CR  - Zhang SY, Lian JS, Hu JH, et al. Clinical characteristics of different subtypes and risk factors for the severity of illness in patients with COVID-19 in Zhejiang, China. Infect Dis Poverty. 2020;9(1):85. doi:10. 1186/s40249-020-00710-6
CR  - Nasir N, Farooqi J, Mahmood SF, Jabeen K. COVID-19-associated pulmonary aspergillosis (CAPA) in patients admitted with severe COVID-19 pneumonia: an observational study from Pakistan. Mycoses. 2020;63(8):766-770. doi:10.1111/myc.13135
CR  - Lamoth F, Glampedakis E, Boillat-Blanco N, Oddo M, Pagani JL. Incidence of invasive pulmonary aspergillosis among critically ill COVID-19 patients. Clin Microbiol Infect. 2020;26(12):1706-1708. doi: 10.1016/j.cmi.2020.07.010
CR  - lanio A, Dellière S, Fodil S, Bretagne S, Mégarbane B. Prevalence of putative invasive pulmonary aspergillosis in critically ill patients with COVID-19. Lancet Respir Med. 2020;8(6):e48-e49. doi:10.1016/S2213-2600(20)30237-X
CR  - Harman EM. Aspergillosis. In: Soo Hoo GW (Ed). Medscape. Updated: May 12, 2021. https://emedicine.medscape.com/article/296052-overview#a5 (Accessed online on June 25, 2024)
CR  - Aspergilloma and AIDS. A comparison of HIV-infected and HIV-negative individuals. Chest. 1997;111(3):612-618. doi:10.1378/chest.111.3. 612
CR  - Meersseman W, Vandecasteele SJ, Wilmer A, Verbeken E, Peetermans WE, Van Wijngaerden E. Invasive aspergillosis in critically ill patients without malignancy. Am J Respir Crit Care Med. 2004;170(6):621-625. doi:10.1164/rccm.200401-093OC
CR  - Rutsaert L, Steinfort N, Van Hunsel T, et al. COVID-19-associated invasive pulmonary aspergillosis. Ann Intensive Care. 2020;10(1):71. doi:10.1186/s13613-020-00686-4
CR  - Bartoletti M, Pascale R, Cricca M, et al. Epidemiology of invasive pulmonary aspergillosis among COVID-19 intubated patients: a prospective study. Clin Infect Dis. 2021;73(11):e3606-e3614. doi:10.1093/cid/ciaa1065
CR  - Helleberg M, Steensen M, Arendrup MC. Invasive aspergillosis in patients with severe COVID-19 pneumonia. Clin Microbiol Infect. 2021; 27(1):147-148. doi:10.1016/j.cmi.2020.07.047
CR  - Mohamed A, Rogers TR, Talento AF. COVID-19 associated invasive pulmonary aspergillosis: diagnostic and therapeutic challenges. J Fungi (Basel). 2020;6(3):115. doi:10.3390/jof6030115
CR  - Lamoth F, Glampedakis E, Boillat-Blanco N, Oddo M, Pagani JL. Incidence of invasive pulmonary aspergillosis among critically ill COVID-19 patients. Clin Microbiol Infect. 2020;26(12):1706-1708. doi: 10.1016/j.cmi.2020.07.010
CR  - Moeller B. Assessing invasive pulmonary aspergillosis incidence in COVID-19 vs Influenza. Pulmonary Advisor. Available at https://www.pulmonologyadvisor.com/home/topics/lung-infection/assessing-invasive-pulmonary-aspergillosis-incidence-in-covid-19-vs-influenza/. April 22, 2021.
CR  - Lamoth F, Lewis RE, Walsh TJ, Kontoyiannis DP. Navigating the uncertainties of COVID-19 associated aspergillosis (CAPA): a comparison with influenza associated aspergillosis (IAPA). J Infect Dis. 2021;224(10):1631-1640. doi:10.1093/infdis/jiab163
CR  - Cennimo DJ. Coronavirus disease 2019 (COVID-19) clinical presentation. In: Bronze MS (Ed). Medscape. Updated: May 01, 2024.https://emedicine.medscape.com/article/2500114-clinical#b3 (Accessed online on June 25, 20214)
CR  - Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review. JAMA. 2020;324(8):782-793. doi:10. 1001/jama.2020.12839
CR  - CDC. Long-term effects of COVID-19. Centers for disease control and prevention. Available at https://www.cdc.gov/coronavirus/2019-ncov/long-term-effects.html. 2020 Nov 13; Accessed: December 1, 2021.
CR  - [Guideline] COVID-19 Treatment Guidelines Panel. Clinical Spectrum of SARS-CoV-2 Infection. National Institutes of Health. Available at https://www.covid19treatmentguidelines.nih.gov/overview/clinical-spectrum/. March 1 2024 (updated); Accessed: February 29, 2024.
CR  - Datta SD, Talwar A, Lee JT. A proposed framework and timeline of the spectrum of disease due to sars-cov-2 infection: illness beyond acute infection and public health implications. JAMA. 2020;324(22):2251-2252. doi:10.1001/jama.2020.22717
CR  - McFadyen JD, Stevens H, Peter K. The emerging threat of (Micro)thrombosis in COVID-19 and its therapeutic implications. Circ Res. 2020;127(4):571-587. doi:10.1161/CIRCRESAHA.120.317447
CR  - Walsh TJ, Anaissie EJ, Denning DW, et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis. 2008;46(3):327-360. doi:10.1086/525258
CR  - Arastehfar A, Carvalho A, van de Veerdonk FL, et al. COVID-19 associated pulmonary aspergillosis (CAPA)-from immunology to treatment. J Fungi (Basel). 2020;6(2):91. doi:10.3390/jof6020091
CR  - Koehler P, Cornely OA, Böttiger BW, et al. COVID-19 associated pulmonary aspergillosis. Mycoses. 2020;63(6):528-534. doi:10.1111/myc. 13096
CR  - Charles MP, Kali A, Easow JM, et al. Ventilator-associated pneumonia. Australas Med J. 2014;7(8):334-344. doi:10.4066/AMJ.2014. 2105
CR  - Torres A, Martin-Loeches I. Invasive pulmonary aspergillosis in ventilator-associated pneumonia: the hidden enemy? Am J Respir Crit Care Med. 2020;202(8):1071-1073. doi:10.1164/rccm.202006-2605ED
CR  - Person AK, Chudgar SM, Norton BL, Tong BC, Stout JE. Aspergillus niger: an unusual cause of invasive pulmonary aspergillosis. J Med Microbiol. 2010;59(Pt 7):834-838. doi:10.1099/jmm.0.018309-0
CR  - Trovato L, Scalia G, Domina M, Oliveri S. Environmental isolates of multi-azole-resistant Aspergillus spp. in Southern Italy. J Fungi (Basel). 2018;4(4):131. doi:10.3390/jof4040131
CR  - Dupont D, Menotti J, Turc J, et al. Pulmonary aspergillosis in critically ill patients with coronavirus disease 2019 (COVID-19). Med Mycol. 2021;59(1):110-114. doi:10.1093/mmy/myaa078
CR  - Schein F, Munoz-Pons H, Mahinc C, Grange R, Cathébras P, Flori P. Fatal aspergillosis complicating severe SARS-CoV-2 infection: a case report. J Mycol Med. 2020;30(4):101039. doi:10.1016/j.mycmed.2020.101039
CR  - Kitayama T, Tone K, Makimura K, Takagi M, Kuwano K. COVID-19-associated pulmonary aspergillosis complicated by severe coronavirus disease: is detection of Aspergillus in airway specimens before disease onset an indicator of antifungal prophylaxis? Cureus. 2023;15(3): e36212. doi:10.7759/cureus.36212
CR  - Koehler P, Bassetti M, Chakrabarti A, et al. Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance. Lancet Infect Dis. 2021;21(6):e149-e162. doi:10.1016/S1473-3099(20)30847-1
CR  - Chong WH, Neu KP. Incidence, diagnosis and outcomes of COVID-19-associated pulmonary aspergillosis (CAPA): a systematic review. J Hosp Infect. 2021;113:115-129. doi:10.1016/j.jhin.2021.04.012
CR  - Cornely OA, Maertens J, Bresnik M, et al. Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). Clin Infect Dis. 2007;44(10):1289-1297. doi:10.1086/514341
CR  - Hatzl S, Reisinger AC, Posch F, et al. Antifungal prophylaxis for prevention of COVID-19-associated pulmonary aspergillosis in critically ill patients: an observational study. Crit Care. 2021;25(1):335. doi:10.1186/s13054-021-03753-9
UR  - https://doi.org/10.38053/acmj.1620027
L1  - https://dergipark.org.tr/tr/download/article-file/4521573
ER  -